& Events
& Events
News
& Events
Mar 30, 2021 Inversago Pharma to present at upcoming Bloom Burton & Co. Healthcare Investor Conference to be held on April 20-21, 2021
MONTREAL (CANADA) – March 30, 2021 – Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference. Details are as follows: Date: Wednesday, April 21, 2021 Time: 4 pm ET Format: 30-minute live virtual presentation, including […]
Jan 7, 2021 Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA for INV-101 for the Treatment of Prader-Willi Syndrome
MONTREAL (CANADA) – January 07, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome (PWS). A Phase I study with INV-101 is […]
Nov 30, 2020 Inversago Pharma continues to rapidly expand its leadership team and appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer
MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as […]
Oct 13, 2020 Inversago Pharma Appoints Michael D. Harvey, PhD as Senior Vice President, Drug Development
MONTREAL (CANADA) – October 13, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing all R&D activities pertaining to CMC, nonclinical development, and regulatory […]
